PMID- 38001474
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20231201
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Nov 25
TI  - Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic 
      control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus 
      patients: a randomized controlled trial.
PG  - 259
LID - 10.1186/s12902-023-01511-2 [doi]
LID - 259
AB  - BACKGROUND AND OBJECTIVE: Type 2 diabetes mellitus (T2DM) is caused by insulin 
      resistance or tissue insensitivity to insulin, as well as relative insulin 
      insufficiency. Diabetes that is uncontrolled for an extended period of time is 
      linked to substantial comorbidities and organ damage. The purpose of the current 
      study is to assess the effect of coadministration of omega-3 fatty acids with 
      glimepiride on blood glucose, lipid profile, serum irisin, and sirtuin-1 levels 
      in T2DM patients. METHODS: This clinical trial involved 70 type 2 diabetic 
      patients randomly assigned to glimepiride 3 mg with either omega-3 capsules 
      contained fish oil 1000 mg, 13% of eicosapentaenoic acid (EPA) and 9% 
      docosahexaenoic acid (DHA) (omega-3 group, n = 35) or placebo capsules contained 
      corn oil and linoleic acid (control group, n = 35) daily for three months. Blood 
      samples were obtained at the start of the study and 12 weeks later for 
      biochemical examination of HbA1c%, FBG, fasting insulin, and lipid profile. In 
      addition, the atherogenic index of plasma (AIP) was calculated. Human 
      enzyme-linked immunosorbent assay (ELISA) kits were utilized for assessing serum 
      irisin and sirtuin-1 levels before and after the intervention. RESULTS: Compared 
      to the control group, omega-3 fatty acids decreased serum fasting blood glucose 
      (FBG, p < 0.001), glycated hemoglobin percent (HbA1C%, p < 0.001), total 
      cholesterol (TC, p < 0.001), triglycerides (TGs, p = 0.006), low density 
      lipoprotein (LDL, p = 0.089), and Homeostatic Model Assessment for Insulin 
      Resistance (HOMA-IR, p = 0.021) after three months of intervention. However, a 
      significant increase was reported in serum irisin and high density lipoprotein 
      (HDL) between both groups after intervention (p = 0.026 and p = 0.007, 
      respectively). The atherogenic index of plasma (AIP) increased in the control 
      group but decreased in the omega-3 group, with significant differences between 
      the two groups (p < 0.001). CONCLUSION: The present study found that 
      supplementing with omega-3 fatty acids might dramatically enhance blood irisin 
      levels, as well as improve glycemic control and lipid profile in type 2 diabetes 
      mellitus patients using glimepiride. TRIAL REGISTRATION: This study is registered 
      on ClinicalTrials.gov under identifier NCT03917940 . (The registration date: 
      April 17, 2019).
CI  - (c) 2023. The Author(s).
FAU - Werida, Rehab H
AU  - Werida RH
AUID- ORCID: 0000-0002-5983-3993
AD  - Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, Damanhour University, 
      Damanhour, 22514, Egypt. rehabwrieda@pharm.dmu.edu.eg.
FAU - Ramzy, Aalaa
AU  - Ramzy A
AD  - Ministry of Health and Population, Damanhour City, Egypt.
FAU - Ebrahim, Youssri Nassief
AU  - Ebrahim YN
AD  - Internal Medicine and Diabetes Department, Damanhour Medical National Institute, 
      Damanhour City, Egypt.
FAU - Helmy, Maged Wasfy
AU  - Helmy MW
AD  - Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, 
      Damanhour, 22514, Egypt.
AD  - Pharmacology and Toxicology, College of Pharmacy, Arab Academy for Science, 
      Technology and Maritime Transport, Abou Keer, Alexandria, Egypt.
LA  - eng
SI  - ClinicalTrials.gov/NCT03917940
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20231125
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Fibronectins)
RN  - 6KY687524K (glimepiride)
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Insulin)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Humans
MH  - Blood Glucose/analysis
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Double-Blind Method
MH  - *Fatty Acids, Omega-3
MH  - Fibronectins
MH  - Glycated Hemoglobin
MH  - Glycemic Control
MH  - Insulin/metabolism
MH  - *Insulin Resistance
MH  - Sirtuin 1
PMC - PMC10675938
OTO - NOTNLM
OT  - Atherogenic index
OT  - Glimepiride
OT  - Irisin
OT  - Omega-3
OT  - Sirtuin-1
OT  - T2DM
COIS- The authors declare no competing interests.
EDAT- 2023/11/25 07:42
MHDA- 2023/11/27 12:42
PMCR- 2023/11/25
CRDT- 2023/11/24 23:49
PHST- 2023/05/25 00:00 [received]
PHST- 2023/11/14 00:00 [accepted]
PHST- 2023/11/27 12:42 [medline]
PHST- 2023/11/25 07:42 [pubmed]
PHST- 2023/11/24 23:49 [entrez]
PHST- 2023/11/25 00:00 [pmc-release]
AID - 10.1186/s12902-023-01511-2 [pii]
AID - 1511 [pii]
AID - 10.1186/s12902-023-01511-2 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2023 Nov 25;23(1):259. doi: 10.1186/s12902-023-01511-2.